Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
Mesoblast Corporate Update and Financial Results Webcast
04:19pm, Thursday, 19'th Nov 2020
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a c
New York, New York--(Newsfile Corp. - November 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
New York, New York--(Newsfile Corp. - November 17, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,
NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1
New York, New York--(Newsfile Corp. - November 11, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Mesoblast Limited (NASDAQ: MESO) alleg
Rosen, National Trial Counsel, Reminds Mesoblast Limited Investors of Important Deadline in Securities Class Action - MESO
05:15pm, Wednesday, 11'th Nov 2020
New York, New York--(Newsfile Corp. - November 11, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,
New York, New York--(Newsfile Corp. - November 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe
Rosen, Top Ranked Investor Counsel, Reminds Mesoblast Limited Investors of Important Deadline in Securities Class Action - MESO
07:15pm, Friday, 06'th Nov 2020
New York, New York--(Newsfile Corp. - November 6, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,
Pomerantz Law Firm Announces the Filing of a Class Action against and Mesoblast Limited Certain Officers - MESO
08:24pm, Friday, 30'th Oct 2020
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its of
LOS ANGELES, Oct. 30, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on beh
Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHD
06:00am, Thursday, 29'th Oct 2020
Quarterly Activity Report Quarterly Activity Report
New York, New York--(Newsfile Corp. - October 28, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1
New York, New York--(Newsfile Corp. - October 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities
